Company intelligence / Profile preview

Kerr

Ownership: Private
Development stage: Commercial

Overview

Kerr Biotech develops innovative medical devices aimed at improving standards of care in wound management. Their Curason Wound Cleaning System is commercially available and registered with the Australian Therapeutic Goods Administration as a wound therapy ultrasound system. No clinical trial data for drugs or biologics was identified, but their device is positioned for enhancing treatment modalities in clinical practice.

Therapeutic areas: Dermatology
Modalities: Device (specifically, wound therapy ultrasound systems)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Kerr.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kerr.

Explore the full profile